Cancer News and Research

Latest Cancer News and Research

Cancer research boosted in Queensland Australia

The University of Queensland's Institute for Molecular Bioscience (IMB) is one of just three recipients of the largest research grant ever given by the Australian Cancer Research Foundation (ACRF).

29 Mar 2004

New research to predict patient response to cancer chemotherapies

Timothy J. Yeatman, M.D., Moffitt's Associate Center Director for Clinical Investigations at the H. Lee Moffitt Cancer Center & Research Institute, and the Sarasota-based DNAPrintTM genomics, Inc., have formed a joint research program to develop and implement new clinical tests for predicting patient response to cancer chemotherapies.

29 Mar 2004

Tadpole research may help fight tumours

There's something magical about tadpoles. The mere mention of this little creature sparks happy memories of children screaming with delight as they splash in a shallow stream trying to capture some of the tiny swimmers in a cup. The real magic happens as the children witness the metamorphosis from tadpole to frog

29 Mar 2004

Enzyme called COX-2 may promote the development of ovarian tumors

Fox Chase Cancer Center scientists have identified how an enzyme called COX-2 may promote the development of ovarian tumors, adding further insight into the mechanism of COX-2 inhibitors and the prevention of this highly lethal disease. The data was presented today at the 95th Annual Meeting of the American Association for Cancer Research in Orlando, Fla.

29 Mar 2004

Researchers tap modified plant viruses to ward off cervical cancer-causing infections

New vaccinations to prevent infections that lead to cervical cancer and targeted therapeutics aimed at breast cancer were examples of research highlights presented by scientists today at the 95th Annual Meeting of the American Association for Cancer Research. Scientists described advances that feed into the drug development 'pipeline,' and show strong promise for controlling existing tumors or addressing the pathogen that causes tumors.

29 Mar 2004

Data on pre-clinical activity of satraplatin in prostate cancer to be released

Spectrum Pharmaceuticals, Inc has announced that new data on pre-clinical activity of satraplatin in prostate cancer cell lines are being presented at the 95th Annual Meeting of the American Association for Cancer Research (AACR) in Orlando, Florida.

29 Mar 2004

Novel vaccine technology to suppress the growth of certain tumors

MedImmune, Inc. and Cerus Corporation have announced preclinical results demonstrating the effectiveness of a novel therapeutic vaccine technology in suppressing the growth of certain tumors.

From Baxter International Inc. 29 Mar 2004

Immunomodulator induces long-term anti-tumor activity

EntreMed, Inc., a clinical-stage biopharmaceutical company developing therapeutic candidates primarily for the treatment of cancer, today reported that three months following administration with ENMD 0996, preclinical animal models showed inhibition of metastases. Data presented demonstrated that ENMD 0996 specifically blocks the activity of basic fibroblast growth factor (FGF-2), a naturally-occurring protein that stimulates angiogenesis, but had no effect on other angiogenesis stimulators.

29 Mar 2004

Colorectal cancer and preventative screening legislation in the US

Even though colorectal cancer is one of the most preventable types of cancer, only 18 US states have enacted legislation requiring insurance providers to cover the cost of preventative screening. These findings from the 2004 Colorectal Cancer Legislation Report Card were released today by the Entertainment Industry Foundation’s National Colorectal Cancer Research Alliance (EIF’s NCCRA) and the American Gastroenterological Association (AGA).

29 Mar 2004

Earlier detection of cancer with Transgenomic's WAVE(R) system

Transgenomic Inc. has announced that during the American Association of Cancer Research annual meeting currently underway in Orlando, several of its customers from major research institutions worldwide will present results in which the Company's WAVE System has played an important role.

29 Mar 2004

Three of the world’s top women chemists visit UK to inspire young scientists

Three of the world’s top women chemists are visiting the UK this week (29 March - 2 April) to tour institutions and talk about their research with the aim of inspiring young scientists to emulate their achievements. The inaugural Rosalind Franklin International Lectureship Programme has been masterminded by Professor Susan Gibson, Imperial College London, who funded the initiative with her prize money from the Royal Society Rosalind Franklin Award.

29 Mar 2004

Halting the development of certain pancreatic, ovarian, colon and lung cancers may be possible with new therapy

By investigating a single molecule that influences cell growth, a research group in the Purdue Cancer Center, including Brian S. Henriksen, has gained new insight into the chain of events that make some cancer cells divide uncontrollably, insight that may eventually lead to a way to break that chain, stopping cancer in its tracks. The molecule, known as Icmt, has a critical role in the development of Ras, an ordinarily beneficial protein that tells a cell to divide. The research group has determined how to inhibit Icmt's influence on Ras, without which the protein cannot develop effectively into an instigator of cell growth.

28 Mar 2004

Haemophilia Society President presents Hepatitis C (HCV) Facts to UK Government

Haemophilia Society President to challenge government for second time in Lords question on proposed Hepatitis C ex gratia payment scheme On Thursday 25 March, the first business in the House of Lords will be further questioning of Ministers by the Haemophilia Society’s President, Lord Morris of Manchester.

27 Mar 2004

Renowned researchers, scientists share advances in prevention, diagnosis, therapy

Leading researchers are gathering today for the 95th Annual Meeting of the American Association for Cancer Research (AACR), the premier multidisciplinary assembly, which features the latest developments in basic, prevention, translational and clinical cancer research. The meeting occurs from March 27 – 31, 2004 at the Orlando Convention Center, Fla.

27 Mar 2004

St. John’s wort may interfere with cancer-fighting drug’s ability to prevent relapse in leukemia patients

St. John’s wort, an herb thought to be a safe, natural remedy for mild depression, may interfere with a powerful cancer-fighting drug’s ability to prevent relapse in leukemia patients, a University of Florida pharmacy researcher will report March 27 at the annual meeting of the American Society for Clinical Pharmacology and Therapeutics.

26 Mar 2004

New patent to develop antibody therapies for cancer and other diseases

The University of Rochester Medical Center and Vaccinex, Inc. announced today the award of a key U.S. patent for a technology platform that can assist researchers in finding new treatments for cancer and other diseases. While the technology has many applications, one promising use is for the identification of certain proteins, called monoclonal antibodies, that are capable of seeking out and destroying harmful cells. Several companies have recently developed monoclonal antibodies as treatments for cancer, rheumatoid arthritis, and other conditions. Under an exclusive, worldwide license from the University of Rochester, Vaccinex is using the patented technology to discover and develop new monoclonal antibody therapies.

26 Mar 2004

Researchers have successfully grafted human breast tissue into the mammary glands of mice

The last few years have witnessed critical advances in breast cancer therapies. Still, the disease afflicts one in eight American women, and scientists have yet to develop a living model with which they can study the intricacies of human breast-tumor behavior.

26 Mar 2004

p53 protein peptide stops cancer in its tracks

Researchers have dreamed of thwarting cancer by using proteins that halt cell growth and kill the tumor. In theory, the approach should work. In practice, however, scientists have not had an easy time of getting tumor suppressor proteins into cells where they can block growth effectively.

26 Mar 2004

Oral chemotherapy agent Orathecin™ (rubitecan) capsules accepted by FDA for filing

SuperGen Inc. announced today that the Food and Drug Administration (FDA) has officially accepted the Orathecin™ (rubitecan) capsules’ New Drug Application (NDA) for filing. Orathecin, an investigational anticancer compound, is an oral chemotherapy agent that has been investigated as a treatment for pancreatic cancer patients who have failed at least one prior chemotherapy.

26 Mar 2004

New computerized tool to assist surgeons in planning cryosurgery

Carnegie Mellon University's Yoed Rabin is leading an interdisciplinary research team in developing a new computerized tool to assist surgeons in planning cryosurgery, now being used to freeze undesired tissues in prostate cancer patients.

26 Mar 2004